The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Multiple myeloma news at ASH 2020
Maria Victoria-Mateos
• 1 Dec 2020
Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, shares developments in the multiple myeloma field that will be discussed at ASH 2020. This includes a focus on BCMA-targeted therapies, both targeted CAR-T cells and bispecific antibodies, as well as novel targets and therapeutics such as talquetamab. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
